Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.

about

Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.

Item

http://www.wikidata.org/entity/Q38726658

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Synergistic disruption of ERα/ ...... atinib in breast cancer cells.

@en

type

Item

label

Synergistic disruption of ERα/ ...... atinib in breast cancer cells.

@en

prefLabel

Synergistic disruption of ERα/ ...... atinib in breast cancer cells.

@en

P1476

Synergistic disruption of ERα/ ...... patinib in breast cancer cells

@en

P2093

James Chun Yip Chan

http://www.w3.org/2001/XMLSchema#string

Pei Shi Ong

http://www.w3.org/2001/XMLSchema#string

Peirong Lim

http://www.w3.org/2001/XMLSchema#string

Preben Xiang Long Teng

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.

PharmGKB summary: tamoxifen pathway, pharmacokinetics

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.

P2888

s00280-016-3211-7

P304

117-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-3211-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eric Chun Yong Chan

P577

2016-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024189265

http://www.w3.org/2001/XMLSchema#string

P698

27942916

http://www.w3.org/2001/XMLSchema#string